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Abstract
Multiple sclerosis (MS) is a complex disorder of the central nervous system that
appears to be driven by a shift in immune functioning toward excess inflamma-
tion that results in demyelination and axonal loss. Beta interferons were the
first class of disease-modifying therapies to be approved for patients with MS
after treatment with this type I interferon improved the course of MS on both
clinical and radiological measures in clinical trials. The mechanism of action of
interferon-beta appears to be driven by influencing the immune system at many
levels, including antigen-presenting cells, T cells, and B cells. One effect of these
interactions is to shift cytokine networks in favor of an anti-inflammatory
effect. The pleiotropic mechanism of action may be a critical factor in deter-
mining the efficacy of interferon-beta in MS. This review will focus on select
immunological mechanisms that are influenced by this type I cytokine.
Introduction
Multiple sclerosis (MS) is a chronic immune-mediated
disease of the central nervous system (CNS) with an
unknown cause.1 In relapsing forms of MS, individuals
experience inflammatory demyelination and subsequent
interruption of axonal function.1 Over time, this damage
to the CNS leads to significant disability and earlier death
in patients with MS than those in non-MS comparators.1
A great deal of research has examined the underlying
pathophysiology of the disease. Many of these efforts have
focused on antigen-presenting cells (APCs), T cells
(including Th1/Th2/Th17 effector cell polarization and
T regulatory [Treg] cells), B cells, and cytokine networks
that participate in the demyelinating process. Disease-
modifying treatments (DMTs) for patients with MS must
simultaneously impact multiple processes that are part of
the immune system including (1) antigen presentation,
(2) T-cell polarization and function, and (3) B-cell
engagement in order to lead to improvements in clinical
outcomes. The focus of this review will be on the immu-
nomodulatory effects of beta interferons, the first class of
DMTs to be approved for the treatment of patients with
relapsing-remitting MS (RRMS).
Natural interferon-beta, type I interferon, is secreted by
fibroblasts and binds to the interferon receptor, which
consists of two components (IFNAR1 and IFNAR2), and
activates the Janus kinase (JAK)/Signal Transducer and
Activator of Transcription (STAT) pathway to phosphory-
late STAT1 and STAT2.2,3 These dimerize and associate
with interferon regulatory factor (IRF) 3 and then bind to
interferon-stimulated response elements in the cell
nucleus.4 This in turn activates interferon-stimulated
genes and leads to the production of antiviral, antiprolif-
erative, and antitumor products.4 Type II interferon
(interferon-gamma) binds to IFNGR1 and IFNGR2, also
activating the JAK/STAT pathway, although the resulting
STAT1 homodimer complex differs from the STAT1/
STAT2/IRF9 complex that is formed by type I interfer-
ons.4 Interferon gamma induces factors with weak antivi-
ral but strong immunomodulatory effects.4
There are two commercially available formulations of
recombinant interferon-beta: interferon beta-1a (intra-
muscular Avonex [Biogen Idec; Cambridge, MA] and
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subcutaneous Rebif [EMD Serono; Rockland, MA]),
which is nearly identical to the natural interferon-beta,
and interferon beta-1b (Betaferon/Betaseron [Bayer
HealthCare Pharmaceuticals; Whippany, NJ] and the
identical Extavia [Novartis Pharmaceuticals Corporation,
East Hanover, NJ]). Interferon beta-1b is expressed in a
bacterial vector such as Escherichia coli and differs from
interferon beta-1a in that it has one less amino acid and
because it is not glycosylated.2 Interferon beta-1b also
contains a serine substitution for cysteine at position 17.5
The clinical efficacy of these agents is derived from
interactions with the immune system at multiple levels.
Importantly, beta interferons appear to counter some
pathogenic processes in MS by affecting the function of
APCs, T cells, and B cells in the adaptive immune system.
The Adaptive Immune System in MS
The adaptive immune system produces antibodies and
T cells that recognize and neutralize potential pathogens
that enter the body.3 To accomplish this task, compo-
nents of this system have both effector and regulatory
functions, which are accomplished by different cell types.3
In patients with MS, the activity of these components is
tipped in favor of an inflammatory response.
The exact cause of MS remains unknown. There is indi-
rect evidence to suggest that MS is triggered by a viral infec-
tion, including the elevated levels of virus-specific
antibodies in serum.6 Virus-specific oligoclonal bands and
elevated immunoglobulin G have also been detected in the
cerebrospinal fluid (CSF) of patients with MS.6 It is possi-
ble that some immunoglobulins may cross-react with or
trigger responses to antigens within the CNS, but no clear
linkage with viruses has been discovered to date. Impor-
tantly, type I interferons are expressed under natural condi-
tions in response to viral infections.2 The role of specific
viral agents responsible for the induction or persistence of
the disease remains speculative and unconfirmed.
Other speculation as to the origin of MS has centered on
bacteria in the gut microbiome. In animal models of demy-
elinating disease, changes in gut microbiota can alter out-
comes.7 For example, mice genetically engineered to
express a myelin basic protein peptide do not develop
spontaneous experimental autoimmune encephalitis (EAE)
when reared in pathogen-free environments.8 However,
these mice will promptly develop EAE when colonized with
commensal gut microbiota.8 In addition, germ-free mice
are unable to mount an inflammatory interleukin (IL)-17-
driven response in an EAE model until they are monocol-
onized with specific commensal bacteria such as segmented
filamentous bacteria.9 Some have also speculated that MS is
caused by an increase in adhesion molecules and a subse-
quent modification in immune reactivity and immune cell
trafficking.10 Dysregulation of key components of the
immune system in patients with MS suggests that the dis-
ease is caused by an overactivity and/or a loss of homeo-
static balance in the immune system,10 which will be
described in greater detail in the following sections.
Regardless of the cause of MS, components of the
adaptive immune system are thought to become activated
and respond to myelin or other targets within the CNS,
leading to inflammatory demyelination and axonal loss.11
Specific CNS antigen(s) have not been isolated; however,
MS is considered to be an immune-mediated disease
characterized by many changes in immune regulation.
This hypothesis suggests that everyone has the potential
to develop MS, but the disease only manifests in certain
people when the appropriate conditions are met. Much of
the work that drives this speculation on disease mecha-
nisms in MS has been derived from the EAE mouse
model.3,11 Care must be taken when applying this model
to human pathology because of the large differences in
cellular regulation and inflammatory gene activation
between humans and mice.12 In addition, EAE will incite
several myelin-derived peptides, whereas in human MS,
this association remains speculative.
APC Function in the Innate Immune
System
Under normal physiological conditions, APCs process and
present non-self-molecules to T cells, which are primed
through interaction with costimulatory molecules on the
surface of the APCs.3 In patients with an autoimmune
disease, APCs process and present proteins that are part
of the patient’s own body.3 In the case of MS, APCs may/
are believed to present myelin antigens in the CNS,3
although evidence supporting this hypothesis is weak.
Among the different types of APCs (i.e., dendritic cells,
monocytes, macrophages, and B cells), dendritic cells are
the most potent type and can be further differentiated
into myeloid or plasmacytoid cells.3 B cells will be dis-
cussed in a separate section below.
T cells are transformed into active phenotypes through
a process of polarization that requires two signals, the
presence of costimulatory proteins, and secreted cytokines
from APCs and lymphocytes (including IL-4, IL-5, IL-6,
IL-12, IL-13, IL-23, and TGF-b), which control the
balance between effectors and regulators in the immune
system.3,13 The first signal in this process occurs when the
peptide-loaded human leukocyte antigen on the APC
binds to the T-cell receptor.3 Once bound, a second co-
stimulatory protein on APCs activates the T cell and trig-
gers the innate immune response.3
Dendritic cells are particularly important in this process
and are activated by toll-like receptors (TLRs) and
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cytokines to provide all of the necessary signals for polari-
zation of na€ıve T cells.3 TLRs are pattern recognition
molecules that are constitutively expressed, primarily on
APCs and, to a lesser extent, on lymphocytes.3 A subtype
of dendritic cells, myeloid dendritic cells, expresses TLR2,
which responds to microbial products and induces den-
dritic cells to secrete IL-12p70 to stimulate T cells.13,14
Plasmacytoid dendritic cells express TLR7 and TLR9
(which respond to microbial nucleic acids) and secrete
type I interferon when activated.13,14 Elevated type I inter-
feron induces Treg phenotypes and Th1 cells.13,15
Although a myelin-specific antigen has not been identi-
fied in patients with MS, such an “MS antigen” would
presumably have some structural similarities with myelin.
However, evidence to back up this assumption is limited.
Support for this hypothesis is derived from experiments
involving the administration of altered peptide ligands in
mice after induction of EAE.16 To date, trials using tissue
from human subjects have not found evidence of myelin-
specific antigens.
In patients with MS, dendritic cell function is shifted
in favor of inflammatory activity (Table 1). For example,
patients with MS have a high number of plasmacytoid
dendritic cells in CSF, which increases further during
relapses.13 These cells express excessive levels of costimu-
latory molecules and Th1-promoting interferon-alpha in
patients with RRMS.13,17 In addition, decreased secretion
of interferon-alpha compared with healthy controls when
the plasmacytoid dendritic cells of patients with MS are
stimulated suggests an impairment in immune regulation
in that plasmacytoid cells have a decreased capacity to
induce mature cell phenotypes.18
Myeloid dendritic cell phenotypes also change with dis-
ease form in patients with MS.13 When the disease reaches
the secondary progressive stage, myeloid dendritic cells
upregulate costimulatory markers that are indicative of a
pro-inflammatory phenotype.13 In contrast, patients with
RRMS typically have myeloid dendritic cells with an imma-
ture phenotype.13 Overall, increased dendritic cell activity
appears to be a key feature in the pathogenesis of MS.
APCs, including dendritic cells, can activate Th1 cells,
which release pro-inflammatory cytokines that enable leu-
kocytes to cross the blood–brain barrier into the CNS.11
The chemokine receptor CCR7 facilitates the entry of
T cells into peripheral lymph nodes and away from the
CNS.11 In patients with MS, there is decreased expression
Table 1. Overview of the immunomodulatory effects of interferon-beta.
Dysfunction in MS Effect of interferon-beta
APCs • May respond to myelin in the CNS
• ↓ Secretion of Th1-promoting interferon-alpha
• ↓ Suppression of dendritic cell activity
• ↑ Expression of pro-inflammatory costimulatory
markers and cytokines
• ↓ Antigen presentation and T-cell stimulation
• ↓ Dendritic cell concentration in peripheral blood
• ↓ TLR9-mediated interferon-alpha secretion
• ↓ Pro-inflammatory cytokine production
T cells • CD8+ cells attack oligodendrocytes
• ↑ Percentage of Th17 cells
• ↓ CD8+ regulatory cells in blood and CSF
• ↑ Apoptosis of pro-inflammatory CD4+ and CD8+ Th17 cells
• ↓ Pro-inflammatory cytokine production
• Channel T cells into lymphoid tissues and thereby reduce
T-cell activation
• ↑ Production of Treg
• ↓T-cell adhesion to blood–brain barrier
B cells • ↑ MHC II
• ↑ CD80+ cells, CD80+/CD86+ ratio
• ↑ Plasma BAFF
• ↓ MHC II expression
• ↓ CD80+ cells
• ↑ IL-10 and TGFb secretion
Cytokine networks • ↑ IL-17 secretion
• ↑ IL-22 secretion leads to increased development
of lymphoid cells
• ↑ IL-23 secretion leads to increased T-cell polarization
• ↓ IL-17 secretion by Th17 cells
• ↑ Secretion of Th2-promoting cytokines (IL-4, IL-5, IL-13)
• ↑ IL-27 secretion increases the induction of Treg
Other effects • ↑ Secretion of MMPs, allowing activated macrophages
to enter the CNS
• Expression of BDNF receptor on neurons and
glia near lesions
• ↓ MMP-9, restore MMP-9/TIMP-1 ratio
• ↑ BDNF secretion, which theoretically could lead to axonal
repair
MS, multiple sclerosis; APCs, antigen-presenting cells; CNS, central nervous system; CSF, cerebrospinal fluid; MHC, major histocompatibility com-
plex; IL, interleukin; TGF, transforming growth factor; BAFF, B-cell activating factor of the TNF family; MMPs, matrix metalloproteinases; BDNF,
brain-derived neurotrophic factor; Treg, regulatory T cell.
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of this receptor on CD8+ effector T cells, which should
increase trafficking of T cells into the CNS.19
Effects of Interferon-Beta on Antigen
Presentation
Interferon-beta reduces myeloid dendritic concentrations
in peripheral blood. It also alters the function of dendritic
cells and other APCs to downregulate antigen presentation
and the ability of APCs to stimulate T-cell responses.20
Beta interferons nonetheless help to maintain the number
of type I interferon-secreting plasmacytoid dendritic cells.13
However, they downregulate TLR9, which decreases TLR9-
mediated secretion of Th1-promoting interferon-alpha
from the plasmacytoid dendritic cells.17 In addition, on
plasmacytoid dendritic cells, interferon-beta upregulates
the expression of TLR3, TLR7, and MyD88, the TLR adap-
tor molecule that is hypothesized to increase immune reg-
ulation and decrease the likelihood of virus-mediated MS
relapses (as well as other anti-inflammatory effects that
have not yet been fully explained).21 In another mecha-
nism, increased CCR7 expression with interferon-beta may
also facilitate the channeling of T cells away from the CNS
and toward peripheral lymph nodes.22 In the CNS, inter-
feron-beta may also alter antigen presentation by mono-
cytes and microglial cells to reduce presentation to
T cells.20,23 These combined effects would potentially
reduce the presentation of myelin-specific antigens.
T-Cell (CD4+ and CD8+) Function
CD4+ and CD8+ T cells recognize antigens through
major histocompatibility complex (MHC) molecules
bound to APCs.3 Once activated, CD4+ T cells become
polarized to differentiate into Th1 cells (also known as
antiviral and antitumor effector T cells, which are
increased in MS) or Th2 cells (which counter Th1 cells
and promote antibody secretion and allergies).3 Both cell
types are involved in different immune-mediated disease
states. CD8+ T cells have two effector phenotypes, with
CD8+ CD28+ cytotoxic lymphocytes functioning as auto-
reactive effectors.24 The CD8+ CD28 suppressor cells
regulate immune function and are critical in MS.24 Effec-
tor T cells are critical for eliminating pathogens, while
regulatory T cells are essential for suppressing immune
activation.3 Patients with MS show evidence of disordered
activity of both aspects of T-cell activity. In MS, Th1 and
Th17 differentiation by activated dendritic cells may be
the primary source of disease pathogenesis.3 Th2 cells,
which can also have an effector phenotype (depending on
the specific disease condition), serve a more regulatory
function in CNS demyelinating disease and inhibit Th1
cells.3
Once activated, T cells secrete pro-inflammatory cyto-
kines that enable them to bind to the endothelial cells
that make up the blood–brain barrier.11 These bound
T cells secrete matrix metalloproteinases (MMPs) that
compromise the extracellular matrix proteins of the su-
bendothelial basement membrane of the blood–brain bar-
rier, thereby allowing activated macrophages to enter the
CNS and demyelinate axons.11 MMP-9 is found in high
levels in the serum and CSF of patients with MS and cor-
relates with disease severity.25,26 Patients with MS also
have a higher ratio of MMP-9 to tissue inhibitor of me-
talloproteinase-1 (TIMP-1), which is the main inhibitor
of MMP-9.27 Within the CNS, macrophages and CD8+ T
cells attack oligodendrocytes, transect axons, and promote
vascular permeability.3,11 This disruption of the blood–
brain barrier is thought to be a critical step in the forma-
tion of demyelinated lesions. These lesions are presumably
the main site of damage to the axon; neurons and glia
near these lesions express receptors for brain-derived neu-
rotrophic factor (BDNF), a trophic factor related to neu-
ronal growth and repair.28 Sites of local inflammation in
the CNS in patients with MS also show decreased Treg
activity, suggesting a loss of control over the inflamma-
tory response.29,30
MS is marked by an increase in the percentage of
T cells that secrete pro-inflammatory IL-17, known as
Th17 cells (Fig. 1A).30 Th17 cells can induce disease, and
neutralization of IL-17 will reduce the symptoms of
EAE.31 In humans, Th17 concentration in peripheral
blood mononuclear cells is generally low in patients with
stable MS as well as in healthy controls but increases sig-
nificantly during active MS.30 IL-17 gene expression is
also high in the CSF of patients with MS, as well as
within MS lesions.32
Levels of IL-17 and the related cytokine IL-22 correlate
with disease activity.30 Furthermore, stimulation with
myelin antigen-specific cells increases the number of
IL-17-secreting cells, which in turn leads to sustained tis-
sue inflammation.30 IL-22, which is a member of the
IL-10 cytokine family and is produced by IL-17-secreting
T cells, may be of particular interest with regard to path-
ogenesis in MS as it plays a critical role in the inflamma-
tory cascade of various autoimmune diseases.33 This
cytokine stimulates the development of innate lymphoid
cells that are gut derived.33 Furthermore, the IL-22RA2
gene has been identified as a risk factor for the develop-
ment of MS.34 All of these findings suggest that Th17 cells
and their related cytokines play a critical role in MS exac-
erbations.
In MS, regulation of the inflammatory response falters.
CD8+ regulatory T cells secrete IL-10, inhibit the matu-
ration of dendritic cells, and secrete transforming
growth factor (TGF)-b, which blocks the activation of
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lymphocytes and normally should reduce the proliferation
of myelin-specific T cells.29 The percentage and function
of the CD8+ CD28 suppressor/regulatory cells in
peripheral blood are reduced in patients with MS relative
to healthy controls, and there is a significant reduction in
these cells during disease exacerbations.35,36 In addition to
a reduction in the number of CD8+ suppressor cells,
patients with active MS also show reduced expression of
CD8 protein on T cells,36 perhaps interfering with thymic
education or regulatory cell effector function. CD8+
CD25+ FOXP3+ regulatory T cells are also reduced in the
CSF of patients with RRMS relative to those with inactive
disease or healthy controls, likely due to excess inflamma-
tion in the CNS.29
Concentrations of CD4+ CD25+ FOXP3+ Treg cells are
low in MS lesions; however, their numbers in peripheral
blood and CSF are increased.37 This finding suggests that
patients with MS do not have an insufficient number of
Treg cells; rather, this regulatory cell population is dys-
functional.37 The dysfunctional CD4+ CD25+ FOXP3+
cell activity in the CNS may also be related to insufficient
trafficking of these cells into the CNS,37 thereby limiting
the ability of this population of Treg cells to curb the
inflammation associated with MS. A picture emerges in
which patients with MS have an increased inflammatory
response without an adequate regulatory response.
Effects of Interferon-Beta on T-Cell-
Mediated Immunity
Consistent with the hypothesis that a broad spectrum of
immunological activity should be maximally effective in
the treatment of patients with MS, interferon-beta exerts
a number of effects on T cells. Through the previously
described mechanisms mediated by APCs, interferon-beta
may indirectly help to control the inflammatory response
in patients with MS by reducing APCs’ ability to activate
T cells.11 Direct effects on T cells also prevent adhesion to
and crossing of the blood–brain barrier.11 Interferon-beta
also facilitates the induction of regulatory T cells, includ-
ing CD4+ CD25+ FOXP3+ Treg cells and CD8+ regula-
tory cells (Fig. 1B).11,38 Through regulation of chemokine
receptors, interferon-beta can also channel autoreactive T
cells into lymphoid tissues and away from the CNS.11
While the decrease in MMP-9 appears to be transient, the
increase in TIMP-1 seems to a more long-lasting
response.39 Other effects at the site of MS lesions can be
seen in the upregulation of the neurotrophic factor
BDNF, which could theoretically lead to neuronal
repair.40
Type I interferons also inhibit Th17 cell differentiation,
thereby reducing the secretion of IL-17 (Fig. 1b).41
In vitro experiments using peripheral blood collected from




















Figure 1. T-cell polarization (A) in patients with untreated MS and (B) under the effects of interferon-beta. Effector and regulatory T-cell
polarization is driven by cytokines that influence the phenotype of the polarized cell. Patients with MS have an increased number of Th17 cells,
which are polarized by IL-6 and TGF-b, leading to increased secretion of pro-inflammatory IL-17.3,30 Interferon-beta inhibits Th17 differentiation,
leading to a decrease in IL-17 secretion.41 In addition to this effector cell phenotype, patients with MS also have a dysregulated Treg response by
Foxp3+ cells that is unable to suppress Th17 cell activity.3 Treatment with interferon-beta increases the number of Foxp3+ cells by increasing
production of IL-4, IL-5, and IL-13, thereby helping to return the secretion of IL-17 by Th17 cells to a level similar to healthy patients.3,45 MS,
multiple sclerosis; IL, interleukin; TGF, transforming growth factor.
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patients with active MS showed that interferon-beta
causes apoptosis in proinflammatory CD4+ and CD8+
Th17 cells in a dose-dependent manner.27,39 Production
of the regulatory protein IL-27 by macrophages is
increased, suppressing the inflammatory response.41
Importantly, IL-27 can significantly inhibit development
of EAE when administered to mice, perhaps by its effect
on the induction of T regulatory cells.41,42 Interferon-beta
also decreases concentrations of TNF in patients with MS;
TNF limits maturation of T cells and should have a nega-
tive effect on T-cell activation in mouse models, but this
effect may not be present in humans.41,43,44 Overall, treat-
ment with interferon-beta is thought to shift cytokine
production in favor of Treg-promoting cytokines, includ-
ing IL-4, IL-5, and IL-13,45 although murine studies46
and data from the Reder laboratory47 find that there is
also a shift to some Th1-promoting cytokines.
B-Cell Function
B cells produce antibodies but also have the capacity to
present antigens and utilize costimulatory proteins to
activate T cells.48 B cells can be APCs48 and are quite
potent when antigen concentrations are low because the
B-cell receptor is antigen specific.49
Through the expression of MHC class II, B cells facili-
tate antigen presentation to CD4+ T cells.49 Once antigen
is bound to the B-cell receptor and is presented to T cells,
the interaction between CD28 on T cells and CD80/CD86
on B cells leads to T-cell activation.50 The costimulatory
proteins CD80 and CD86 that are expressed on B cells
also facilitate T-cell differentiation into effector or regula-
tory cells via their interaction with CD40 on B cells and
its T-cell ligand CD154.49 This is followed by CD80+ cell
activation of Th1 cells for a pro-inflammatory effect and
CD86+ cell activation of Th2 cells for a regulatory effect
via their interaction with the specific T-cell costimulatory
molecules CD28 and CTLA-4.49 Interferon-beta reduces
CD80 on B cells, likely interrupting this highly specific
B-cell arm of immunity.49,51 B cells also produce the criti-
cal anti-inflammatory cytokine, IL-10, that has profound
anti-inflammatory effects by modulation of the migration
of dendritic cells, activation of macrophages, and regula-
tion of B- and T-cell functioning.49,51
In MS, recent clinical trials utilizing B-cell depletion
(via ocrelizumab52 or rituximab53) also suggest that
B cells would be critical for the presentation of the neuro-
and other antigens that are hypothesized to exist in MS
and also for the secretion of cytokines to enhance T-cell
function. B cells may also be responsible for the produc-
tion of autoimmune antibodies to these antigens. Evi-
dence for dysregulated B-cell functioning can be seen in
the increased number of CD80+ cells in the blood of
patients with active MS.48 This increased inflammatory
effect does not appear to be countered by a regulatory
effect, as the ratio of CD80+ to CD86+ cells is also higher
in patients with active MS than in healthy controls.48
Patients with MS also have an elevated number of CF80
(B7.1)-expressing B cells.48,50 B cells of patients with MS
also have a reduced capacity to secrete IL-10, suggesting a
lack of regulatory modulation (up or down) of dendritic
cell activity.49,51 Furthermore, within the meningeal spaces
of the CNS (the germinal center-like areas), B cells pro-
duce inflammatory mediators that stimulate plasma cells
to produce immunoglobulins, which appear as oligoclonal
bands in CSF.49 B-cell activating factor of the TNF family
(BAFF) is elevated in the blood of patients with MS.54
This crucial factor for maintenance of B cells is induced
at sites of inflammation and can exacerbate local inflam-
mation by stimulating the survival of B cells.54 BAFF is
also expressed in MS lesions.55
Effects of Interferon-Beta on B-Cell
Function
Interferon-beta therapy induces changes in B-cell func-
tioning that alter antigen presentation. Expression of
MHC II on B cells is decreased after treatment with inter-
feron-beta through reduction in costimulatory CD80,
which should attenuate antigen presentation to CD8+
T cells.20,48 Also, the number of CD80+ B cells is
decreased with interferon-beta treatment, bringing the
ratio of CD80+ to CD86+ cells closer to that of healthy
controls.48,50 The decrease in CD80-expressing cells may
result from an interferon-beta-mediated decrease in the
production of interferon gamma or other cytokines that
induce CD80+ B cells.48 In addition, treatment with inter-
feron-beta increases the number of CD86 (B7.2)-express-
ing B cells.50 This increase in CD86+ cells should
contribute to the downregulation of Th1 cell responses.50
BAFF levels in blood leukocytes and serum are also
increased with interferon-beta treatment, suggesting a
consequential increase in B-cell functioning.54 With the
right combination of stimuli, this could lead to increased
B-cell secretion of the anti-inflammatory cytokines IL-10
and TGF-b, suggesting that interferon-beta could induce
CD4 and CD8 Treg as well as regulatory B cells.56 The
benefits of the induction of regulatory B cells could
depend on the characteristics of the patient, as B-cell
induction could have undesirable consequences for
patients with B-cell-mediated disease.54
Conclusions
Type 1 interferons have a wide range of effects on the
immune system that can be associated with shifts in
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specific immune-mediated pathways that are involved in
MS disease pathogenesis. Through various mechanisms,
interferon-beta affects antigen presentation, potentially
shifts Th1/Th2/Th17 polarization to a more anti-inflam-
matory state, increases regulatory T-cell and B-cell activ-
ity, and reduces the ability of B cells to present antigens.
Attempts have been made to identify biomarkers for
treatment response. For example, nonresponders to inter-
feron-beta treatment (based on magnetic resonance imag-
ing criteria) show decreased IL-10 levels during the
course of treatment.57 Treatment nonresponders may also
have a lower IL-10/interferon-gamma and IL-4/inter-
feron-gamma ratio than responders.40 The same study
found that nonresponders had lower BDNF levels at base-
line than responders.40 Induction of TIMP-1, the main
inhibitor of MMP-9, may also be a marker of response to
interferon-beta.39 Differences in molecular signatures
include upregulation of many genes related to immune
regulation, but also into protective and antioxidant pro-
files in most treated patients.58 In parallel, an exaggerated
molecular response to interferon-beta in a subset of
patients with MS has been associated with a poor
response to treatment.59 While these and other findings
suggest that biomarkers for treatment response may exist,
more research is needed before these can be put into clin-
ical practice.
Interestingly, current data would suggest that effective
therapy for patients with MS requires intervention in
some combination of immune compartments. For exam-
ple, T-cell-specific therapies such as ustekinumab, an anti-
IL-12/IL-23 antibody, failed to reduce the cumulative
number of new lesions in a phase 2 trial.60 Also, the anti-
CD4 antibody, cM-T412, produced long-lasting reduc-
tions in circulating CD4+ T cells, but this alone did not
affect the number of active lesions in patients with MS.61
In a third approach, T-cell vaccination did not produce
clinical or radiological improvements in previously treated
patients with RRMS.62 In addition to these T-cell-targeted
therapies, the fusion protein atacicept, which limits BAFF
binding and B-cell maturation, actually increased inflam-
mation in a phase 2 trial.63 In contrast, the B-cell-specific
anti-CD20 antibody, rituximab, which destroys B cells
and may also impact the capacity of B cells to present
antigens to T cells, was very effective at reducing MS
relapses.63,64 These studies suggest that some therapeutic
approaches to treatment of patients with MS that target
only one immunologic pathway or process may differ in
effectiveness relative to those that affect the immune sys-
tem at multiple levels. Notably, the very late antigen-4
antagonist natalizumab remains the exception to this
hypothesis as it has a very focused mechanism of action
but has clear efficacy in patients with RRMS.65 Interferon-
beta, which has pleiotropic effects on immunity and brain
cells, may be considered a broad spectrum therapeutic.
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